Relating to medical treatments with investigational products.
HB 3799 creates a state framework allowing Oregon health care practitioners to offer investigational, not-yet-FDA-approved drugs, biological products, or devices to adult Oregon residents who have a terminal disease or a severe chronic disease. The bill defines who qualifies, requires the patient to be capable and acting voluntarily, and limits use to treatment related to the patient’s condition. It also requires disclosure of the experimental nature of the product, known risks, likely costs, available alternatives such as palliative care and hospice, and the option of federal expanded-access pathways.
Before treatment can proceed, the patient must be referred by an attending physician, evaluated by a consulting physician, and, if there are concerns about impaired judgment due to psychiatric or psychological conditions, referred for counseling. The patient must sign a detailed election form in the presence of two witnesses, including a waiver of liability for non-gross-negligent acts related to administering, manufacturing, or distributing the investigational product. The bill also requires insurers to be notified when a covered patient elects treatment, but it does not require insurers to pay for the treatment or related adverse effects.
The bill’s main legal effect is to provide civil and criminal liability protections, and to limit professional discipline, for practitioners, facilities, professional organizations, manufacturers, and distributors that comply with the act. It also allows health care facilities or practitioners to prohibit participation on their premises and creates consequences for violating those prohibitions. In addition, the bill states that hospice eligibility cannot be denied solely because a patient is receiving or has received this type of investigational treatment.
HB 3799 also adds oversight and reporting requirements. The Oregon Health Authority must review a sample of records each year, collect information on referrals and treatments, and publish an annual statistical report, while keeping underlying records nonpublic except as otherwise required by law. The bill therefore expands access to experimental treatment while pairing that access with documentation, reporting, and patient-consent safeguards.
No committee transcripts or recorded votes were provided, so there is no direct evidence of formal legislative debate or vote sentiment in the materials supplied. Based on the bill text alone, the measure appears designed to support patient access and physician discretion, while also trying to reduce legal risk for providers and manufacturers. Likely points of contention include the liability waiver, the lack of insurance reimbursement, the use of investigational products outside FDA approval, and the balance between patient autonomy and protections against coercion or impaired judgment.
The bill would create a new statutory scheme in Oregon law governing the use of investigational products for adults with terminal disease or severe chronic disease. It would add definitions, consent procedures, physician referral and confirmation requirements, liability protections, insurer noncoverage rules, hospice protections, and Oregon Health Authority reporting duties. It would affect health care practitioners, health care facilities, professional associations, manufacturers, distributors, insurers, and patients seeking experimental treatment.
No committee discussion or voting history was provided, so there is no documented legislative sentiment to summarize from those sources. From the bill text, the measure appears broadly supportive of patient access to experimental treatment and protective of participating providers, but it also includes significant safeguards and limits that suggest an effort to address safety, voluntariness, and oversight concerns. The overall tone is permissive but regulated.
The most likely points of contention are whether Oregon should authorize treatment with FDA-unapproved products outside traditional pathways, whether the required liability waiver is appropriate, and whether patients should bear treatment and manufacturing costs without insurance reimbursement. Additional concerns may include the adequacy of informed consent, the risk of coercion or exploitation of seriously ill patients, and whether the bill’s protections for providers and manufacturers go too far. Supporters would likely emphasize patient autonomy, access to potentially beneficial therapies, and legal certainty for clinicians; opponents would likely focus on safety, evidence standards, and consumer protection.